
From left to right, Francisco José López Cano, Arturo Rodríguez-Banqueri, F. Xavier Gomis-Rüth and Marina Girbal González.
Photo Credit: Courtesy of University of Barcelona
Scientific Frontline: Extended "At a Glance" Summary: Celiacase and Celiac Disease Therapeutics
The Core Concept: Celiacase is a molecularly engineered enzyme designed to break down toxic gluten immunogenic peptides (GIPs) in the stomach before they can reach the small intestine and trigger an autoimmune response.
Key Distinction/Mechanism: Unlike existing glutenases that require a neutral pH and high doses to function in the duodenum, celiacase operates highly effectively at very low concentrations in the acidic environment of the stomach (pH 2). It works synergistically with pepsin and completely deactivates upon reaching the intestine, preventing unintended interference with other proteins in the body.
Major Frameworks/Components:
- Pathophysiology of Celiac Disease: Prolamins (such as wheat gluten) break down during digestion into toxic peptides, most notably the highly immunogenic α-gliadin '33-mer' fragment.
- Autoimmune Trigger Mechanism: The binding of GIPs to the human leukocyte antigen (HLA) receptor in the small intestine, which initiates a damaging inflammatory response.
- Molecular Engineering: The derivation, structural design, and optimization of the celiacase molecule based on the naturally occurring nephrosin enzyme.
- In Vivo Validation: Efficacy demonstrated in a specialized mouse model, exhibiting reductions in intestinal atrophy, inflammation, antibody responses, and dysbiosis, alongside the restoration of normal immunoregulatory markers and microbial metabolic pathways.



.jpg)

.jpg)
.png)




.jpg)

.png)